[go: up one dir, main page]

MA34170B1 - Inhibiteurs de transcriptase inverse non nucléosidiques - Google Patents

Inhibiteurs de transcriptase inverse non nucléosidiques

Info

Publication number
MA34170B1
MA34170B1 MA35324A MA35324A MA34170B1 MA 34170 B1 MA34170 B1 MA 34170B1 MA 35324 A MA35324 A MA 35324A MA 35324 A MA35324 A MA 35324A MA 34170 B1 MA34170 B1 MA 34170B1
Authority
MA
Morocco
Prior art keywords
reverse transcriptase
transcriptase inhibitors
compounds
nucleoside reverse
hiv
Prior art date
Application number
MA35324A
Other languages
English (en)
Inventor
Jason Burch
Bernard Cote
Natalie Nguyen
Chun Sing Li
Miguel St-Onge
Danny Gauvreau
Original Assignee
Merck Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44710363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34170(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Canada Inc filed Critical Merck Canada Inc
Publication of MA34170B1 publication Critical patent/MA34170B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

LES COMPOSÉS HÉTÉROAROMATIQUES DE FORMULE I : (I) SONT DES INHIBITEURS DE TRANSCRIPTASE INVERSE DU VIH, LES RADICAUX R1, R2, R3, R4 ET R5 ÉTANT TELS QUE DÉFINIS DANS LA PRÉSENTE INVENTION. LES COMPOSÉS DE FORMULE I ET LEURS SELS DE QUALITÉ PHARMACEUTIQUE PEUVENT ÊTRE EMPLOYÉS DANS L'INHIBITION DE LA TRANSCRIPTASE INVERSE DU VIH, DANS LE TRAITEMENT PROPHYLACTIQUE ET THÉRAPEUTIQUE D'UNE INFECTION PAR LE VIH ET DANS LE TRAITEMENT PROPHYLACTIQUE, LE RETARD DE L'APPARITION OU DE LA PROGRESSION, OU LE TRAITEMENT THÉRAPEUTIQUE DU SIDA. LES COMPOSÉS ET LEURS SELS PEUVENT ÊTRE EMPLOYÉS EN TANT QU'INGRÉDIENTS DANS DES COMPOSITIONS PHARMACEUTIQUES, ÉVENTUELLEMENT COMBINÉS À D'AUTRES AGENTS ANTIVIRAUX, IMMUNOMODULATEURS, ANTIBIOTIQUES OU VACCINS.
MA35324A 2010-03-30 2011-03-28 Inhibiteurs de transcriptase inverse non nucléosidiques MA34170B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31882410P 2010-03-30 2010-03-30
US32157310P 2010-04-07 2010-04-07
PCT/CA2011/000320 WO2011120133A1 (fr) 2010-03-30 2011-03-28 Inhibiteurs de transcriptase inverse non nucléosidiques

Publications (1)

Publication Number Publication Date
MA34170B1 true MA34170B1 (fr) 2013-04-03

Family

ID=44710363

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35324A MA34170B1 (fr) 2010-03-30 2011-03-28 Inhibiteurs de transcriptase inverse non nucléosidiques

Country Status (45)

Country Link
US (2) US8486975B2 (fr)
EP (2) EP2552902B1 (fr)
JP (2) JP5281718B2 (fr)
KR (1) KR101421861B1 (fr)
CN (1) CN102971308B (fr)
AR (1) AR080859A1 (fr)
AU (1) AU2011235568B2 (fr)
BR (1) BR112012024691B1 (fr)
CA (1) CA2794377C (fr)
CL (1) CL2012002744A1 (fr)
CO (1) CO6630126A2 (fr)
CR (1) CR20120503A (fr)
CY (3) CY1118774T1 (fr)
DK (2) DK2552902T3 (fr)
DO (1) DOP2012000256A (fr)
EA (1) EA024804B1 (fr)
EC (1) ECSP12012201A (fr)
ES (2) ES2536295T3 (fr)
FI (1) FIC20190021I1 (fr)
GE (1) GEP20156368B (fr)
HK (2) HK1175471A1 (fr)
HN (1) HN2012002039A (fr)
HR (2) HRP20150427T1 (fr)
HU (4) HUE031785T2 (fr)
IL (2) IL222030A (fr)
LT (3) LT2924034T (fr)
LU (2) LUC00113I9 (fr)
MA (1) MA34170B1 (fr)
ME (2) ME02181B (fr)
MX (1) MX2012011379A (fr)
MY (1) MY163979A (fr)
NI (1) NI201200146A (fr)
NL (1) NL300980I2 (fr)
NO (2) NO2019019I1 (fr)
NZ (1) NZ602670A (fr)
PE (1) PE20130158A1 (fr)
PH (1) PH12012501923A1 (fr)
PL (2) PL2552902T3 (fr)
PT (2) PT2924034T (fr)
RS (2) RS54017B1 (fr)
SG (1) SG184347A1 (fr)
SI (2) SI2552902T1 (fr)
TN (1) TN2012000455A1 (fr)
TW (1) TWI458719B (fr)
WO (1) WO2011120133A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011120133A1 (fr) * 2010-03-30 2011-10-06 Merck Frosst Canada Ltd. Inhibiteurs de transcriptase inverse non nucléosidiques
CN103517990A (zh) 2010-10-07 2014-01-15 通用医疗公司 癌症生物标志物
WO2014052171A1 (fr) * 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Forme cristalline d'inhibiteur de transcriptase inverse
JO3470B1 (ar) * 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
BR112015012843B8 (pt) * 2012-12-05 2023-04-25 Merck Sharp & Dohme Método para sintetizar o composto
KR102601617B1 (ko) * 2013-11-22 2023-11-10 머크 샤프 앤드 돔 엘엘씨 비-뉴클레오시드 역전사 효소 억제제의 조성물
WO2015084763A2 (fr) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Procédé de préparation d'inhibiteurs de transcriptase inverse
AU2015241247B2 (en) 2014-04-01 2017-09-14 Merck Sharp & Dohme Llc Prodrugs of HIV reverse transcriptase inhibitors
EP3760208B1 (fr) 2014-06-25 2024-05-29 The General Hospital Corporation Ciblage de hsatii (human satellite ii)
HUE056978T2 (hu) 2015-12-02 2022-04-28 Merck Sharp & Dohme Doravirint, tenofovir-dizoproxil-fumarátot és lamivudint tartalmazó gyógyszerészeti kompozíciók
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
CA3060222A1 (fr) 2017-04-18 2018-10-25 Cipla Limited Polytherapie destinee a etre utilisee dans le traitement d'infections retrovirales
EP4317972A3 (fr) 2018-02-06 2024-03-13 The General Hospital Corporation Arn à motifs répétés utilisés comme biomarqueurs de réponse immunitaire tumorale
EP3823632A4 (fr) * 2018-07-17 2022-04-20 Merck Sharp & Dohme Corp. Combinaison de médicaments contre le vih pour augmenter la barrière contre la résistance
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用
CN114163309B (zh) * 2021-12-27 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体的制备方法
CN114349690B (zh) * 2022-02-15 2023-04-25 甘肃皓天医药科技有限责任公司 一种多拉韦林中间体合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904045D0 (sv) 1999-11-09 1999-11-09 Astra Ab Compounds
TW200423930A (en) 2003-02-18 2004-11-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitors
EP1608629A1 (fr) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinones en tant qu inhibiteurs de transcriptase inverse
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
ES2333802T3 (es) 2004-04-23 2010-03-01 F. Hoffmann-La Roche Ag Inhibidores no nucleicos de transcriptasa inversa.
CA2592092A1 (fr) 2004-12-22 2006-06-29 Pfizer Limited Composes chimiques
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
DE602006005699D1 (de) 2005-10-19 2009-04-23 Hoffmann La Roche N-phenyl-phenylacetamid-nichtnukleosidinhibitoren reverser transkriptase
BRPI0617720A2 (pt) 2005-10-19 2011-08-02 Hoffmann La Roche compostos inibidores de nnrt de fenil-acetamida, usos dos referidos compostos e composição farmacêutica que os contém
TW200831085A (en) 2006-12-13 2008-08-01 Merck & Co Inc Non-nucleoside reverse transcriptase inhibitors
RU2010125220A (ru) 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
WO2011120133A1 (fr) * 2010-03-30 2011-10-06 Merck Frosst Canada Ltd. Inhibiteurs de transcriptase inverse non nucléosidiques

Also Published As

Publication number Publication date
PL2924034T3 (pl) 2017-07-31
EA201290976A1 (ru) 2013-03-29
BR112012024691B1 (pt) 2020-11-17
FIC20190021I1 (fi) 2019-04-17
NI201200146A (es) 2013-03-18
RS55505B1 (sr) 2017-05-31
CY2019025I2 (el) 2019-11-27
TW201139409A (en) 2011-11-16
WO2011120133A1 (fr) 2011-10-06
ES2536295T3 (es) 2015-05-22
LTPA2019506I1 (lt) 2019-04-25
PL2552902T3 (pl) 2015-10-30
CN102971308A (zh) 2013-03-13
JP5281718B2 (ja) 2013-09-04
IL233334A (en) 2015-09-24
ES2609636T3 (es) 2017-04-21
LT2924034T (lt) 2016-12-27
HRP20150427T1 (hr) 2015-07-03
JP2013510800A (ja) 2013-03-28
TWI458719B (zh) 2014-11-01
CN102971308B (zh) 2015-02-04
DK2552902T3 (en) 2015-06-15
LUC00113I2 (fr) 2024-05-22
HUS1900022I1 (hu) 2019-05-28
ME02181B (me) 2015-10-20
TN2012000455A1 (en) 2014-01-30
AR080859A1 (es) 2012-05-16
CY2019026I1 (el) 2020-05-29
CY2019025I1 (el) 2019-11-27
RS54017B1 (en) 2015-10-30
HN2012002039A (es) 2015-08-24
HRP20161680T1 (hr) 2017-01-27
CY1118774T1 (el) 2017-07-12
LTC2552902I2 (lt) 2019-12-10
CA2794377A1 (fr) 2011-10-06
LTC2924034I2 (lt) 2020-10-12
ME02570B (me) 2017-06-20
CA2794377C (fr) 2015-06-16
CL2012002744A1 (es) 2012-12-14
MY163979A (en) 2017-11-15
SI2552902T1 (sl) 2015-10-30
JP5886790B2 (ja) 2016-03-16
NO2019018I1 (no) 2019-04-24
HK1209121A1 (en) 2016-03-24
US8486975B2 (en) 2013-07-16
EP2552902A4 (fr) 2013-09-04
HUE031785T2 (en) 2017-08-28
PT2552902E (pt) 2015-06-02
CO6630126A2 (es) 2013-03-01
JP2013209405A (ja) 2013-10-10
AU2011235568A1 (en) 2012-11-01
US20130296382A1 (en) 2013-11-07
EA024804B1 (ru) 2016-10-31
IL222030A (en) 2014-07-31
EP2924034A1 (fr) 2015-09-30
CR20120503A (es) 2013-01-09
LTPA2019507I1 (lt) 2019-04-25
PH12012501923A1 (en) 2013-02-04
MX2012011379A (es) 2012-11-30
SG184347A1 (en) 2012-11-29
PT2924034T (pt) 2017-01-06
HK1175471A1 (en) 2013-07-05
EP2552902B1 (fr) 2015-03-11
BR112012024691A2 (pt) 2019-07-02
ECSP12012201A (es) 2012-10-30
EP2552902A1 (fr) 2013-02-06
KR101421861B1 (ko) 2014-07-22
LUC00114I1 (fr) 2019-04-17
NZ602670A (en) 2014-09-26
HUE025336T2 (en) 2016-03-29
NL300980I1 (nl) 2019-04-24
EP2924034B1 (fr) 2016-11-02
DOP2012000256A (es) 2012-12-15
NO2019019I1 (no) 2019-04-24
LUC00113I9 (fr) 2024-06-07
AU2011235568B2 (en) 2013-09-12
HUS1900021I1 (hu) 2019-05-28
CY2019026I2 (el) 2020-05-29
PE20130158A1 (es) 2013-02-28
GEP20156368B (en) 2015-09-25
IL233334A0 (en) 2014-09-01
NL300980I2 (nl) 2021-06-17
US20110245296A1 (en) 2011-10-06
KR20120128703A (ko) 2012-11-27
SI2924034T1 (sl) 2017-05-31
LUC00114I2 (fr) 2020-07-10
DK2924034T3 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MA34002B1 (fr) Thérapie antivirale
MA44674A (fr) Inhibiteurs de bromodomaine
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
EA201590674A1 (ru) Производные 5-фенокси-3h-пиримидин-4-она и их применение в качестве ингибиторов обратной транскрипазы вич
MA29745B1 (fr) Inhibiteurs de la transcriptase inverse du vih
MA42292A (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
MA40123A1 (fr) Pyrimidines utilisées en tant qu'inhibiteurs du facteur xia
CR8569A (es) Inhibidores de integrasa de vih
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA43960B1 (fr) Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
JOP20210075A1 (ar) مشتقات 4-بيرازين-2-يل ميثيل-مورفولين واستخدامها كدواء
MX2015012575A (es) Novedosos derivados de acrilamida como agentes contra la malaria.
FR3058640B1 (fr) Composes pour leur utilisation dans le traitement de la grippe